• First Tracks Biotherapeutics closed its previously announced private placement of 6,106,870 common shares on October 19, 2026.
• A registration rights agreement requires filing or confidentially submitting an SEC registration statement covering investors' share resales within 30 days of closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Tracks Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-426666), on October 20, 2026, and is solely responsible for the information contained therein.